I want to begin by extending my warmest congratulations to Aether Biomachines on its newly announced $15 million Series A1 financing.
This is more than a fundraising announcement.
It marks a milestone seven years in the making—the moment Aether fully steps into its identity as a product company, not just a discovery platform.
And speaking personally, it is a moment I’m incredibly proud to witness.
There are moments in venture investing when the future feels unusually clear.
That moment arrived for me when I recently met with Jay Zaveri, who has now joined Aether full-time as President and Cofounder.
Jay was already Aether’s largest investor through Natural Capital, but in person, in an operating role, he radiated a different kind of clarity. He spoke about Aether with the precision of a scientist and the urgency of an operator. What impressed me most was how plainly he could articulate the opportunity in front of the company — not in abstractions, but in hard numbers, customer pull, and near-term scaling milestones.
As he described the surging demand for RapidPrint, Aether’s first commercial material, I felt something shift. This was no longer an early-stage R&D project. This was a company crossing into commercial inevitability.
That’s when I realized:
Aether had reached its inflection point.
When we first invested in Aether, the company’s vision was daring: to build a full-stack molecular manufacturing platform capable of designing and producing novel enzymes that could manufacture entirely new classes of materials.
It was a moonshot — but one grounded in deep science.
For years, Aether resembled a modern Bell Labs: building generative AI models, engineering enzymes never seen in nature, inventing new biochemical pathways, and collecting the functional data needed to power a next-generation protein design engine.
This kind of platform work is slow, rigorous, and often invisible.
But then, suddenly, it wasn’t.
Aether launched RapidPrint, an AI-designed polymer engineered to replace aluminum in additive manufacturing. It didn’t just work — it landed in real customers’ hands.
And that changed everything.
RapidPrint is already being used by aerospace manufacturers, defense primes, and U.S. government labs. Forbes recently profiled the explosion of demand for materials that outperform legacy metals — particularly in high-heat, high-strength, high-throughput environments.
One of the most vivid examples comes from Ukraine.
Drone maker Wild Hornets publicly shared that they operate over 350 3D printers nonstop, even through power outages and wartime conditions. Their production tempo is staggering — drone arms, lattice structures, internal supports, thermal housings — all printed continuously.
RapidPrint’s strength-to-weight ratio, heat resistance, and mechanical tunability aren’t just impressive; they’re commercially catalytic.
This is what product-market fit looks like in deep tech.
To understand how Aether made this leap, you need to understand its core engine:
The Protein Function Model (PFM) — Aether’s function-conditioned transformer that designs proteins based on the behaviors we want them to perform.
PFM begins with the desired industrial function — catalytic rate, binding behavior, thermal stability, and mechanical resilience — and then generates protein sequences capable of delivering that outcome. This flips the traditional paradigm:
🧬 Not “Given this sequence, what might it do?”
🧬 But “Given what we want done, what sequence should we build?”
Behind this model is one of the world’s fastest functional protein data engines. Aether tests ~300 proteins per week, generating 7,000+ functional readouts across catalytic reactions, binding affinity, pH stability, solute tolerance, temperature, and pressure behaviors — all feeding into the model in a continuous experimental feedback loop.
To visualize how Aether maps protein structure to protein function, this early video remains a striking illustration of their computational foundation:
And for a deeper explanation of the Protein Function Model — its architecture, data strategy, and implications for molecular manufacturing — Aether’s own technical deep dive is an excellent resource:
👉 “A Future for Abundant Manufacturing”
PFM isn’t just an AI model; it is the blueprint of a new industrial paradigm. It enables programmable biochemistry for applications ranging from supermaterials to
mineral extraction
CO₂ conversion
pharmaceutical synthesis
plastics manufacturing
PFAS breakdown
The horizon is vast. And now, with RapidPrint, the horizon is real.
This is why Jay’s decision to join Aether full-time matters enormously. His background — deep-tech investing at Social Capital and Natural Capital, building and scaling companies, early conviction in enzyme-driven manufacturing — gives Aether exactly what it needs now: operational force behind scientific breakthroughs.
As Jay put it in his LinkedIn post
“This is the kind of company I’ve always wanted to build: one at the core of programmable biochemistry — with the potential to create a future of abundance.”
With Jay and Pavle together, Aether now has both sides of the equation:
🧪 the scientific engine
🏭 the manufacturing roadmap
📈 the commercial pull
🚀 the leadership to scale
The next chapter is no longer discovery.
It is deployment.
Our follow-on investment in this round is driven by conviction — in the team, in the technology, and in the timing.
Aether now has:
✔ Product-market fit
✔ A commercially validated first product
✔ A breakthrough biochemical AI platform
✔ A leadership team built for the manufacturing era
✔ Strategic partners such as Henkel — a global leader in specialty materials and adhesives, validating Aether’s industrial potential
✔ A clear path to scaling new industrial supply chains
Henkel’s endorsement is particularly meaningful. As one of the world’s leaders in engineered materials, Henkel’s partnership signals that Aether’s science is not just novel — it is industrially viable and commercially inevitable.
These partnerships accelerate adoption, expand go-to-market pathways, and position Aether as a future cornerstone of advanced materials manufacturing.
Very few companies survive the journey from frontier science to industrial scale.
Fewer still turn a platform into a product.
A rare few turn a product into proof of a new industrial paradigm.
Aether is doing all three.
It is an honor to support their next chapter — and to help usher in a world where molecular manufacturing, powered by AI-designed enzymes, becomes a defining technology of the century.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.